New Validated Method for Quantification of Glycated Hemoglobin by LC-QToF-MS: Is HRMS Able to Quantify Clinical Samples?

LC-HRMS and GC-MS Profiling of Urine Free Cortisol, Cortisone, 6Β-, and 18-Hydroxycortisol for the Evaluation of Glucocorticoid and Mineralocorticoid Disorders

INTRODUCTION

Urine free cortisol measurements are routinely performed to evaluate hypercortisolism. Despite their analytical inaccuracy, immunoassay-based methods are frequently used. Advances in liquid chromatography-high-resolution mass spectrometry (LC-HRMS) facilitate the incorporation of powerful diagnostic tools into clinical laboratories. In addition to its high analytical specificity and simultaneous analysis of different metabolites, accurate mass measurement allows for untargeted compound identification, which may help to identify clinically relevant metabolites or drugs.

METHODS

The present study aimed to validate a simple routine LC-HRMS method to quantify cortisol, cortisone, 6β-hydroxycortisol, and 18-hydroxycortisol simultaneously in human urine. Additionally, the study also validated a GC-MS method for the same steroids, evaluated their cross-reactivity with commercial cortisol immunoassays, and quantified the 24 h urine excretion in patients under clinical suspicion or follow-up for hypercortisolism.

RESULTS

The LC-HRMS method involved liquid-liquid extraction using dichloromethane, micro-LC for chromatographic separation and detection using the accurate masses of the steroids, and simultaneous high-resolution full scan acquisition. The method presented acceptable linearity, precision, and accuracy. Significant interference from 6β-hydroxycortisol and cortisone was demonstrated in the cortisol immunoassays, which impacted their reliability in the follow-up of patients with hypercortisolism and significant changes in these cortisol metabolites (i.e., due to drug-induced changes in CYP3A4 activity).

CONCLUSION

A rapid and accurate routine LC-HRMS method was validated, which is useful for the evaluation of hypercortisolism and other disorders of glucocorticoid and mineralocorticoid metabolism.

Biomolecular Surface Functionalization and Stabilization Method to Fabricate Quantum Dots Nanobeads for Accurate Biosensing Detection

The surface functionalization of quantum dots (QDs) is essential for their application as a label material in a biological field. Here, a protein surface functionalization approach was introduced to combine with silica encapsulation for the sustainable and stable synthesis of QDs nanobeads for biomarker detection. The formation of QDs nanobeads was achieved by multiple mercapto groups in bovine serum albumin (BSA) macromolecules as multidentate ligands to replace hydrophobic ligands on the surface of QDs and decompression. The resulting QDs nanobeads exhibited 20 times more photoluminescence than the corresponding hydrophobic QDs and presented excellent stability under physiological conditions due to the protection of BSA and silica. The nanobeads served as a robust signal-generating reagent to construct the lateral flow immunoassay (LFIA) biosensor for the detection of glycosylated hemoglobin (HbA1c). The concentration of HbA1c was determined within 10 min with high specificity using only 60 μL of whole blood samples collected clinically. The nanobeads-based LFIA biosensor exhibited linear detection of HbA1c from 4.2% to 13.6%. The accuracy and stability of this approach in clinical utility was demonstrated by the detection of HbA1c after a long-term storage of test strips. This protein surface modification technology provides a new way for improving the biological properties of QDs in clinical diagnosis.